FRANKLIN LAKES, N.J., Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp ...
BD is pairing up with Labcorp to develop a new line of companion diagnostics for cancer treatments and therapies for other diseases, analyzing patients’ cells using flow cytometry technology to match ...
Medical technology company Becton, Dickinson and Co. is partnering with life sciences company Labcorp to develop cytometry-based companion diagnostics that can be used to match patients with ...
Accurate and timely diagnosis of inborn errors of immunity (IEI) is essential for improving patient outcomes. Flow cytometry is widely recommended for robust and sensitive IEI screening; however, no ...
Serious infections can be immediately life threatening: with serious invasive infections a single day can be the difference between life and death. Despite this urgency, standard practice in pathology ...
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the worldwide commercial launch of a new automated instrument, BD FACSDuet Premium Sample Preparation System. It prepares ...
Flow cytometers are becoming the instrument of choice in a growing number of applications, including marine biology, cancer biology, drug screening, cell-cycle analysis, intracellular analysis, rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback